A comprehensive systematic review and meta-analysis of the global data involving 61,532 cancer patients with SARS-CoV-2 infection

Emma Khoury, Sarah Nevitt, William Rohde Madsen, Lance Turtle, Gerry Davies, Carlo Palmieri
doi: https://doi.org/10.1101/2021.12.18.21267261

Abstract

Background SARS-CoV-2 have been shown to be associated with more severe disease and death in cancer patient. A systematic review and meta-analysis was conducted to determine the risk by age, tumour type and treatment of infection with SARS-CoV-2 in cancer patients.

Methods Systematic review by searching PubMed, Web of Science, and Scopus for articles published in English up to June 14, 2021 of SARS-CoV-2 infection in >10 patients with malignant disease. Outcomes included factors in patients with malignant disease that may predict a poor outcome from COVID-19 compared to patients without malignant disease, including patient demographics, tumour subtype and cancer treatments. A meta-analysis was performed using random effects model.

Results 81 studies were included, totalling 61,532 cancer patients. Haematological malignancies comprised 22.1% (9,672 of 43,676) of cases. Relative risk (RR) of mortality when age and sex matched was 1.69 (95% CI, 1.46-1.95; p<0.001; I2=51%). RR of mortality, versus non-cancer patients, was associated with decreasing age (exp(b)0.96; 95% CI, 0.922–0.994; p=0.028) but not male sex (exp(b)1.89; 95% CI, 0.222–6.366; p=0.83). RR of mortality in those with haematological malignancies versus non-cancer control was 1.81 (95% CI, 1.53-2.95; I2=0.0%). Compared to other cancers, increased risk of death was seen for lung (RR 1.68, 95% CI, 1.45-1.94; p<0.001), genitourinary (RR 1.11; 95% CI, 1.00-1.24; p=0.059) and haematological malignancies (RR 1.42; 95% CI, 1.31-1.54; p<0.001). Breast (RR 0.51; 95% CI, 0.36-0.71; p<0.001) and gynaecological cancers (RR 0.76; 95% CI, 0.62-0.93; p=0.009) had lower risk of death. Receipt of chemotherapy had greatest overall pooled mortality risk of 30% (95% CI, 25-36%; I2=86.97%) and endocrine therapy the lowest at 11% (95% CI, 6-16%; I2=70.7%).

Conclusions Cancer patients, particularly younger cancer patients, appear at increased risk of mortality from COVID-19 compared to non-cancer patients. Differences in outcomes were seen based on tumour types and treatment.

Highlights

  • - To our knowledge this is the largest review and meta-analysis of COVID-19 in cancer patients with insights into tumour types and therapies.

  • - In unadjusted analysis cancer doubles the risk of COVID-19 related mortality. This decreased when adjusted for age and sex.

  • - Younger cancer patients have the highest risk of mortality when compared to non-cancer COVID-19 patient of a similar age.

  • - Patients with lung, genitourinary and haematological malignancies are at increased risk of mortality, breast and gynaecological cancers are at lower risk.

  • - Patients on chemotherapy have the highest pooled mortality risk with those on endocrine therapy the lowest.

Introduction

Individuals with cancer are more prone to respiratory viruses as a result of immunosuppression from either the underlying disease or therapy. This has previously been demonstrated with influenza, which is associated with an increased mortality rate in patients with solid and haematological malignancies 1,2. While rhinovirus alone, if present before hematopoietic cell transplant, is associated with substantial increase in mortality 3. Given this, and since the emergence of the SARS coronavirus 2 (SARS-CoV-2) pandemic, there has been an intense and focused global effort to understand the impact on cancer patients of infection with SARS-CoV-2 and the outcomes with COVID-19.

Understanding the possible risks, consequences, and complications of SARS-CoV-2/COVID-19 in patients with cancer is important for patients, family, and health care systems. For patients and their families such information is key to enable informed decisions around the potential risks of anti-cancer treatment undertaken during the pandemic as well as the degree they should limit social and familial interactions. While for health-care systems, these data are vital to enable informed decisions regarding treatment risk, how to protect cancer patients as well as how best to prioritise a heterogenous population, based on cancer type and treatment, for preventive measures and anti-viral treatments. Such information is also vital in planning the response to future pandemics.

The first large population level data regarding outcome of patients with COVID-19 came from data from the United Kingdom’s pandemic protocol, International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK). This revealed that 10% of the 20,133 hospitalised patients with COVID-19, as of 3rd May 2020, had a history of malignancy. A significant increase in hospital mortality was reported in those patients with a history of malignancy (HR 1.13; 95% CI, 1.02-1.24; p=0.017) 4. While population level data from the Intensive Care National Audit and Research Centre (ICNARC) has found a lower proportion of patients with cancer admitted to intensive care as compared to a retrospective cohort of patients with other viral pneumonias (non-COVID-19), 2.5% versus 5.8% respectively 5. As well as immunosuppressed patients having increased likelihood of death if admitted to critical care 6.

Numerous cancer-specific studies have been undertaken as part of the effort to understand COVID-19 in cancer patients. These have found cancer patients and to have a more severe disease course, with older cancer patients 7–27, and those with haematological malignancies reported to be at particular increased risk 7,8,11,23,28–33. However, many of these studies report disparate results, particularly regarding the association of cancer type and recent cancer treatment with outcomes 10,15,23,34,35. These studies varied in size, nature and were limited by a lack of, or only a very small comparator non-cancer groups 12,14,16,18,19,21,23,26,29,36–45 as well as selectivity in which tumour types of cancer therapies were included in their analysis 9,11,18,23,25,29,32,40,43,46–59. The lack of a contemporaneous age and sex matched non-cancer population, variability in data collection and reporting as well as variable follow up times also limits the published cohort studies. In those studies where a non-cancer cohort was utilised, these were historical patients or based on registry data 36. Given all these factors, confounding biases may be present as a result of unmeasured confounders.

In the current study we undertook a systematic and unbiased review and meta-analysis of all the available published data to investigate the outcomes of patients with SARS-CoV-2 as well as identifying factors which may predict for a poor outcome. Such research and information is key to further our understanding of the impact of the SARS-CoV-2 pandemic as well as identifying possible novel risk factors in cancer patients not identified in previous cohort studies.

Methods

Search strategy and literature search

We undertook a systematic review of the published literature and reported our findings according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines 60. Repeated searches of PubMed, Web of Science and Scopus databases were performed up to 14th June 2021. References from all identified articles were also reviewed to check for other relevant studies with duplicates identified and removed. Search strategies and results from the literature search are shown in Tables S1-S3.

Study selection

Two authors (E.K. and C.P.) independently screened all titles and abstracts after initial de-duplication. The inclusion criteria were any case-control or cohort study with or without a control non-cancer COVID-19 group published in English as a full text article involving patients with cancer and confirmed or suspected SARS-CoV-2 infection or COVID-19, which describe one or more of: the incidence, presentation, management, or outcome of cancer patients with COVID-19. We excluded studies with fewer than 10 patients, conference papers or abstracts, preprints, articles where the full text could not be extracted, studies where data could not be obtained by contacting the corresponding author and animal studies. Where studies with overlapping datasets were present, the paper with the largest and most up to date cohorts were included. Discrepancies were resolved by consensus.

Data extraction and quality assessment

Two authors (E.K. and C.P.) independently undertook data extraction for the following: first author, study type, time period of data collection, country of data collection, number of male and female patients, median or mean age, cancer treatment intervals prior to COVID-19 diagnosis or hospitalisation, unadjusted and adjusted odds ratios (ORs) or hazard ratios (HRs) for severe disease and death for each cancer subtype and for each cancer treatment subtype as well as the number of cancer patients with COVID-19 and cancer type. We collected data on seven cancer subtypes; breast, gynaecological, genitourinary, skin, gastrointestinal, lung and haematological malignancies, as outcome data for these subtypes was most frequently reported within our pool of 81 studies. Data was collected on participant characteristics, global distribution of the studies, setting of care and presenting symptoms.

The quality of the included studies was assessed using the Newcastle-Ottawa scale (NOS) for case control and cohort studies (Figure S1) 61. The eight questions within this scale were arranged into three groups: selection, comparability, and outcomes. Studies can earn a maximum of four stars from selection, two form comparability and three from outcomes, with a maximum score of 9 stars.

Outcomes and statistical analysis

The main outcome of interest was mortality. We performed meta-analysis comparing mortality in cancer patients with COVID-19 to control patients (with COVID-19 but without cancer) and in cancer patients with each tumour subtype compared to cancer patients who did not have that subtype. We also performed meta-analysis pooling case fatality rates for patients with each tumour subtype and those who had received each type of cancer treatments.

For meta-analysis of mortality comparing cancer patients and controls and comparing cancer patients with and without tumour subtypes, results are presented as pooled risk ratio (RR) and 95% confidence intervals (CIs). Meta-analyses of case fatality rate by tumour subtype and cancer treatment results are presented as pooled proportions and 95% CIs.

As statistical heterogeneity was anticipated due to expected variability in study design and participant characteristics, all meta-analyses were conducted using a random effects model, with restricted maximum likelihood to estimate between-studies heterogeneity. Statistical heterogeneity was quantified using the I2 statistic. To examine the impact of age and sex on mortality among cancer patients and controls, random-effects meta-regressions were conducted. Meta-analysis and meta-regression were conducted in Stata version 14.1 using commands admetan 62, metaprop 63 and metareg 64. Additional supplementary figures (of study characteristics were produced in R version 4.0.4 (Figures 4, Figure S3 – 6, S9, S11 & S14a-b).

Results

The initial search retrieved 1,150 articles for review (Figure S2). After the inclusion of records identified through additional sources and removal of duplicate articles, 1,004 records were screened. We obtained 215 articles to assess for eligibility. Of these, 134 were excluded (see Figure S2 for reasons). Eighty-one studies were included in this systematic review and meta-analysis.

Global distribution of studies

Eighty-one studies were included in this systematic review, with a total of 61,532 cancer patients with COVID-19 (Figure S3, Table S4). 61 were retrospective 7,8,10–14,16–25,29–32,36–45,48,49,53–55,57–59,65–85, 17 were prospective 4,26–28,33,35,46,50–52,56,86–91 and three were retro-prospective studies, whereby data were collected on both patients eligible prior to study commencement and those who enter the study post study commencement 9,15,47. Patients were recruited across 28 countries and 5 continents (Figure 1, Figure S4, Table S5). Of the 80 studies that provided information on recruitment by country, the five countries contributing the most patients were: USA, United Kingdom, Italy, France, and China.

Figure 1
Figure 1

Distribution of patients across 80 studies.

Patient characteristics and cancer types

Ten of 81 studies (12%) included cancer patients amongst a cohort that included non-cancer patients with COVID-19 4,44,65,72,75,79,80,84,86,89,91; however, the majority of studies (n=71, 88%) reported on cohorts of cancer patients only. The number of cancer patients in the 81 reports ranged from 11 to 38,614. Where data were available, 52% (30,557 of 58,849) were male, age ranges from 10 to 98 years (median age range 35 to 74 years). The most frequent comorbid conditions reported were hypertension, diabetes mellitus, cardiovascular and pulmonary disease (Figures S5 – S7 & S10b and c). The majority (34,117; 55%) were hospitalised patients and the remainder were outpatients or unknown (Figure S9 and Table S7).

The majority of reports (n=55, 68%) included patients with both solid and haematological malignancies (total of 55,668 patients). 18 (22%) reported on patients with haematological malignancies alone (n=2,526 patients) 11,17,18,23,25,29,32,40,43,50,51,53,54,56,58,59,67,77. Of these 18 studies: four reported exclusively on multiple myeloma and two on chronic lymphocytic leukaemia (CLL) patients. While 8 (10%) studies reported exclusively on patients with solid malignancies 9,46–49,52,55,57, of these, 2 studies each reported on thoracic cancers 46,49, gynaecological cancers 48,57 and breast cancer 52,55. Tumour type was reported in 68 studies (84%) for 43,676 patients (71%) (Table S6). The most frequent were haematological malignancies representing 9,672 (22.1%) of patients followed by breast 8,322 (19.1%); genito-urinary 7,624 (17.4%); skin and melanoma 6,613 (14.1%); gastrointestinal 4,124 (9.4%) and thoracic cancer 2,104 (4.8%). For 1,139 patients (2.6%), the tumour type was documented as other or unknown (Figures S8 & S10A).

Presenting symptoms of SARS-CoV-2 infection

Fifty-three (65%) of the 81 studies, involving 9,196 patients, reported presenting symptoms. The most commonly reported symptoms were fever, cough, dyspnoea, fatigue/malaise, diarrhoea, and myalgia (Figures S10 & S11). The time from onset of symptoms to hospitalisation ranged between 1-40 days, where reported 10,46,48,53,66,69,78.

Radiological findings

Radiological findings of thoracic imaging based on chest radiograph, CT scanning or a combination of chest radiograph and CT scan in cancer patients with COVID-19 were available in 28 studies (n=3,650 patients) 10,13,14,17,25,31–33,35,39,42,43,45,50,52,54–58,66,69,78,81,83–85,87. A total of 19 (26%) studies (n=3,086 patients) provided details of radiological changes (Table S8) 10,13,14,25,31–33,35,39,42,43,50,52,54,56,66,78,85,87. CT features of ground glass opacity, patchy shadows, fibrous stripes, pleural thickening, bilateral involvement, and tumour pulmonary involvement in cancer patients were associated with worsening severity of COVID-19 disease 14,35,66,78,85,87.

Mortality of cancer patients compared with controls

Nineteen of 81 studies (23.5%), compared patients with cancer and COVID-19 to a cohort of patients without cancer and COVID-19 12,14,16,18,19,21,23,26,29,36–43,45. The details of these studies, the matching of the cohorts and the nature of the cohort without cancer and COVID-19 are described in Table 1.

View this table:
Table 1.

Comparison of malignant versus non-malignant patients with outcomes in 19 studies.

* Denotes studies looking at patients with haematological malignancies.

We conducted a meta-analysis of these 19 studies. The pooled relative risk (RR) of mortality in cancer patients with COVID-19 compared with non-cancer control patients with COVID-19 was 2.12 (95% CI, 1.71-2.62, p<0.001, I2 = 84.4%, Figure 2a). When pooling results, the relative risk for mortality in 13 studies that matched for age was reduced to RR 1.69 (95% CI, 1.46-1.95; I2 = 51%; p<0.001) compared to RR 3.80 (95% CI, 2.53-5.71; I2=81.9%, p<0.001) from six studies without matching (Figure 2b). There was little difference in the pooled RR of mortality between any type of malignancy, solid or haematological, (RR 2.23; 95% CI, 1.68-2.95; I2=88.7%) and haematological malignancies (RR 1.81; 95% CI, 1.53-2.95; I2=0.0%) alone compared to non-cancer control patients, respectively (Figure S12).

Figure 3
Figure 3

Forest plot of relative risk of mortality in analysis.

A) Unadjusted mortality risk due to presence of malignant disease. B) Relative risk of mortality due to the presence of malignant disease, after matching for age and gender.

Fourteen studies provided data on the median or mean age of cancer patients and non-cancer patients with COVID-19 14,16,18,19,21,23,26,29,39–43,45. On univariate regression, when assessing the impact of age on the comparison of cancer and control patients, the RR of mortality statistically significantly decreased as age increased (exp (b) 0.96; 95% CI, 0.922 – 0.994; p = 0.028), shows a greater difference in the relative risk of mortality between cancer patients and controls of younger ages (Figure 3a). Seventeen studies reported the sex (as proportion of males) of both cancer and non-cancer control groups 14,16,18,19,21,23,26,29,37–45. A small increase in RR of mortality between cancer patients and controls was shown as the proportion of males in the study increased, but this was not statistically significant (exp (b) 1.89; 95% CI, 0.222–6.366; p=0.83; Figure 3b). When the combined impact of age and proportion of males was explored by multivariable regression, age remained significant (p=0.029) and male sex not significant (p=0.545) (Table S9).

Figure 3
Figure 3

Meta-regression bubble plot results of impact of age and gender.

(A) Risk ratio of mean or median age in cancer vs non cancer subgroups. (B) Risk ratio of male

Clinical outcomes

Outcome data were available for 56,932 patients with cancer and COVID-19 from 68 (84%) of the 81 studies 7–29,31–59,66–70,74,75,77,78,81–84,87,89,90. Where reported, 7.1% (1,170 of 16,409) were admitted to intensive care unit (ICU) and 5.2% (2,817 of 54,298) required invasive mechanical ventilation (IMV) (Table S10). At the time of reporting, 10.7% (473 of 4,403) of patients remained hospitalised and 64.5% (2,841 of 4,403) were discharged. Median duration of hospital stay is shown in Table S11. Of the 56,932 cancer patients, 6,813 died (12%). Median follow up times varied between 5 and 69 days. Mortality was reported in all studies and ranged from 3.7% to 61% (Figure 4, Table S12). Of note, one study defined mortality as either transfer to hospice or death 22.

Figure 4
Figure 4 Mortality reported across 81 studies.

14 different definitions of severe events were used across the studies (Figure S13). 12 studies reported information on ethnicity and outcomes, (summarised in supplementary results document). In unadjusted analyses, several factors were found to be significantly associated with severe events or death. These included increasing age (in 36 studies), raised pro-inflammatory (in 14 studies) and infection related markers (in 14 studies), Figure S14a. Factors found to be significantly associated with worsening severity or mortality, in adjusted analysis are shown in Figure S14b, of which 22 studies found increasing age to be associated with worsening severity or death 7–27. Factors included in adjusted analysis are listed in Figure S15.

Mortality and case fatality rate by cancer type

Pooled case fatality rate forest plots for each cancer subtype are shown in Figure S16. There was a 9% (95% CI, 7% to 12%, I2 = 89.8%; range: 0% to 100%) pooled case fatality rate for patients with breast cancer with a RR of mortality of 0.51 (95% CI, 0.36-0.71; p<0.001; I2=86.2%) when compared with those with non-breast cancers and COVID-19 (Figure 5a). The pooled case fatality rate of patients with COVID-19 and gynaecological cancers was 12% (95% CI, 8%-16%; I2 = 38.47%; range: 0% to 38%) and an associated RR of 0.76 (95% CI, 0.62-0.93; p=0.009; I2= 0%), between those with gynaecological cancers and patients with non-gynaecological cancers (Figure 5b).

Figure 5
Figure 5

Forest plot of relative risk of mortality in the subgroup analysis.

A) Breast cancer and COVID-19, compared to patients with non-breast cancers and COVID-19. B) Gynaecological cancer and COVID-19, compared to patients with non-gynaecological cancers and COVID-19.

Gastrointestinal cancers were associated with a pooled case fatality rate of 16% (95% CI, 12-20%; I2=78.66%; range 0% to 38%) and a RR of 1.13 (95% CI, 0.93-1.37; p=0.207; I2=54.8%) compared to patients with non-gastrointestinal cancers (Figure S17b). Skin cancer was associated with a pooled case fatality rate of 10% (95% CI, 5% to 15%; I2=62.57%; range: 5% to 50%) and a relative risk of mortality of 0.85 (95% CI, 0.60-1.20; p=0.353; I2=51.4%; Figure S17a).

The pooled case fatality rate of patients with COVID-19 and lung cancers was 30% (95% CI, 24%-37%; I2=83.71%; range: 0% to 60%). The RR of mortality in those with lung cancer compared to other cancer types was significantly higher at 1.68 (95% CI, 1.45–1.94; p<0.001; I2 = 32.9%, Figure 6a). Pooled case fatality rate for genitourinary cancers was 22% (95% CI, 16% to 27%; I2=92.61%; range: 8% to 50%), with a RR of mortality of 1.11 (95% CI, 1.00-1.24; p=0.059; I2 = 21.5%,) when compared to non-genitourinary cancers (Figure 6b). The pooled case fatality rate in patients with haematological malignancies was 32% (95% CI, 28%-37%; I2=93.10%; range: 11% to 100%). The overall relative risk of mortality in cancer patients with haematological malignancies, compared to those with solid malignancies is 1.42 (95% CI, 1.31-1.54; p<0.001; I2=6.8%, Figure 6c).

Figure 6
Figure 6

Forest plot of relative risk of mortality in subgroup analysis.

Relative risk of mortality in different cancer types: A) Patients with lung cancer and COVID-19 compared to patients with non-lung cancers and COVID-19. B) Patients with genitourinary cancer and COVID-19 compared to patients with non-genitourinary cancers and COVID-19. C) Patients with haematological malignancies and COVID-19 compared to patients with non-haematological malignancies and COVID-19.

Stage of malignancy and outcome

There was variability with regards to the reported effect of stage of malignancy on outcomes with COVID-19. In unadjusted analysis, 8 studies have reported stage IV disease (of solid cancers) to be associated with significantly higher risk of severe events and mortality compared to patients with stage I, II or III disease 9,10,14,21,66,68,83,85. However, five studies found no association with metastatic primary disease late stage of disease and rates of hospitalisation or mortality 22,30,31,35,46. A study of 181 patients in Brazil found that those with 2 or more metastatic sites had an overall increased risk of death 26.

Cancer treatment and course of COVID-19

Data on timing of cancer treatment and outcome were available in 64 of 81 (79%) of the reported studies (Figure S18). These studies comprised 54,335 patients of whom 7,567 (13.9%) had undergone or received some form of treatment for their malignant disease. Where data was available, the commonest treatment modality was chemotherapy (n=3,792), followed by targeted therapy (n=1,700) and immunotherapy (n=817). 3,896 patients were reported as not having received any form of treatment.

Surgery, within 3 months of a diagnosis of COVID-19 in cancer patients was associated with a pooled case fatality of 19% (95% CI, 9%-29%; I2=58.49%; range: 0% to 40%, Figure S18a). These studies in general looked at all patients, aside from one which was focused on surgery for gynaecological malignancies 48. Patients with cancer who had received chemotherapy and were diagnosed with COVID-19 had an overall pooled case fatality of 30% (95% CI, 25%-36%; I2=86.97%; range: 10% to 100%, Figure S18b). While endocrine therapy had a pooled mortality risk of 11% (95% CI, 6%-16%; I2=70.68%; range: 0% to 27%, Figure 18c). 9 studies did not specify which cancer subtype was treated with endocrine therapy. Immunotherapy was associated with a pooled case fatality of 19% (95% CI, 16%-28%; I2=36.98%; range: 0% to 50%, Figure S18d). Two of these studies specified the tumour involved, lung cancer 49 and gynaecological cancer 48, with the remaining studies not specifying tumour type. Mortality following radiotherapy was available in 10 studies, with a pooled case fatality of 23% (95% CI, 12%-33%: I2=74.84%; range: 0% to 50%, Figure S18e). Tumour type treated, gynaecological, was specified in only one study 48. Targeted therapy was associated with an overall risk of mortality of 18% (95% CI, 12%-23%; I2=59.72%; range: 0% to 57%, Figure S18f). The nature of the targeted therapy was not specified in most cases and the specific cancer type was only stated in 4 of 19 studies (21%): two involving patients with haematological malignancies 25,58, and one respectively for patients with lung 49, and gynaecological cancer and COVID-19 48. These data are in Table S13.

Discussion

From the start of the SARS-CoV-2 pandemic, there has been a focus to identify the patients at greatest risk of poor outcome from infection. Patients with malignant disease were rapidly identified as one such group 92. Initial reports of SARS-CoV-2 infection in cancer patients were small and retrospective 26,43,57,58,81,82,90, subsequently larger collaborative registry studies, prospective and retrospective, have been reported 4,7,37,46,47,93,94. These studies have varied in geographical location and focus with regards to tumour type (Table S4). This systematic review and meta-analysis sought to analyse in an unbiased fashion this important global effort by the cancer community by reviewing all of the available and published data as of the June 14th 2021. The aim being to understand the impact of cancer type, stage and treatment on outcomes from COVID-19 as well as identifying possible novel risk factors in cancer patients not identified in previous studies.

This systematic review demonstrates a number of potential limitations with the currently available data and literature these include; (1) lack of contemporaneous non-cancer populations for comparative analysis 12,19,23,36,38,40; (2) heterogeneity of definitions between studies such as severity of COVID-19 as demonstrated by the 14 definitions of severity used across studies (Figure S13;) (3) predominantly retrospective nature of studies (Table S4, 75%); (4) variable follow up; (5) heterogeneity or poor description of the non-cancer control cohorts, such as use of non-hospitalised patients 12,21,29,36–38,44, or staff members with COVID-19 43; and (6) lack of detail relating to systemic cancer treatment 4,11,12,22,29,33,37,39,41,42,50,52,55–57,65,70–72,75,76,79–81,84,86–91. In those studies where a non-cancer cohort was utilised these data were generally historical or based on registry data and were not contemporaneous to the cancer cohort 12,19,36,38,43. Only three of the 19 studies that compared cancer cohort to a matched non-cancer cohort used propensity score matching 14,16,39. Therefore, within the published literature biases may be present as a result of unmeasured confounders.

Utilising data from 19 studies with 3,926 patients with 38,847 non-contemporaneous non-cancer patients, we found that malignant disease is associated with an increased risk of severe or death from COVID-19 compared with non-cancer patients (RR 2.12; 95% CI, 1.76-2.62; p<0.001; I2=84.4%). In particular, we demonstrate via regression analysis that younger age is associated with a worse clinical outcome relative to age matched non-cancer patients. To date, all the cohort studies, which by their nature have lacked an age matched control, have consistently reported increasing age as a risk factor for poor clinical outcome 7–27. While it is true older patients have a worse absolute outcome than younger patients, the relative risk, as shown in this review, is highest for the younger patients. This observation has been reported within the International Severe Acute Respiratory and emerging Infections Consortium (ISARIAC) WHO Coronavirus Clinical Characterisation Consortium (CCP-Cancer UK) 93,94. In the most recently presented analysis of over 20,000 cancer patients compared with 155,000 non-cancer patients, patients aged less than 50, particularly on active treatment, were five times more likely to die than similar aged non-cancer patients (<50 years, HR 5.22; 95% CI, 4.19 to 6.52; p <0.001). When compared with non-cancer patients the relative risk of death (the cancer attributable risk) fell with age 94. The reasons for this are likely to be related to the type of cancers, more intensive treatments, or possibly behavioural factors such as increased social mixing as compared with an older population.

Our meta-analysis also demonstrates that cancer patients with COVID-19 are twice more likely to die compared to non-cancer matched cohorts. However, when we matched these patients for age and sex, the risk decreased to 1.69 (95% CI 1.46-1.95, p<0.001; I2=51%). This risk, while significant, is lower than that reported by studies that did not match for these factors, where the risk was nearly four times greater in the cancer cohort 26,36,38,41,43,44. This demonstrates that there has been a potential overestimation of the true risk to cancer patients in studies that did not adjust for these factors. This also highlights the critical importance of a comparator non-cancer cohort in understanding the true effects of SARS-CoV-2 within the cancer population. We did not observe any significant differences in outcome by sex when cancer and non-cancer patients were compared again, this is different from a number of studies which have reported male sex as a risk factor 7,10,18,22,23,28,31,66.

Our study found that patients with lung cancer, followed by haematological malignancies, were at greatest risk of mortality from COVID-19, when compared with patients with other cancers. Haematological malignancies have been consistently reported as being a risk factor for poor outcome from COVID-19 7,8,11,23,28,31,32 and the current meta-analysis demonstrates that such patients are 1.42 times (95% CI, 1.31-1.54; p <0.001; I2=6.8%) more likely to die compared with other cancer patients and 1.8 times (95% CI, 1.53-2.95; I2=0.0%) more likely to die compared with non-cancer COVID-19 patients. The increased susceptibility of patients with haematological malignancy is in keeping with the more profound immune suppression that affects this patient group. The increased in mortality with lung cancer (RR 1.68; 95% CI, 1.45–1.94; p<0.001; I2 = 32.9%) compared with patients without lung cancer is likely a reflection of age, the reduced lung reserve, associated co-morbidities associated, and possible effects of cancer treatment. The reason for the lower mortality from COVID-19 seen in patients with breast and gynaecological malignancies is not clear. It could be related to the protective effect of the female sex although we find no difference in outcomes based on sex with our meta-analysis. A possible alternative explanation relates to the hormonal milieu in these patients, with patients with both breast and gynaecological cancers have low circulating oestradiol levels. Breast cancer patients by virtue of the fact they are generally post-menopausal and often on aromatase inhibitors. While treatment for gynaecological cancers often necessitate removal of the ovaries. The possible influence of endocrine therapy has been reported for patients with prostate cancer where the use of androgen deprivation therapy has been associated with a protective effect from SARS-CoV-2 infection 38. There is an ongoing need to dissect the impact of female sex hormones on infection with SARS-CoV-2 as well as the course of COVID-19.

With regard to cancer treatments our pooled case fatality analysis found endocrine therapy to have the lowest pooled case fatality rate at 11% with chemotherapy having the highest at 30%. The higher mortality seen with chemotherapy compared to other treatments is likely reflective of the immunosuppressive effects chemotherapy. Cohort studies have reported disparate findings with regard to the risk of chemotherapy, with some finding significant increase risk of death 8,9,26,28,36,40,46,66,85, and others finding no association 13–16,20,24,25,27,30,31,34,35,48,58,68,74. The lack of patient level data means we have been unable to define the risk of mortality for cancer patients receiving anti-cancer therapy who develop COVID-19. Similarly, for a comparison of the impact of cancer treatment on the risk of mortality when compared to non-cancer patients. A comparison of risk by different treatment modalities as well as by individual agents also was not possible given it was not clear if patients had received more than one treatment modality and individual drugs were not named. For a more informed approach and discussion regarding the risk of different anti-cancer therapy in the context of COVID-19 will require more granular information as well as a comparison to a non-cancer population controlled by age and sex.

This systematic review and meta-analysis has a number of limitations given the nature of the data published and available for analysis. Firstly, we assessed outcomes in 7 tumour types as outcome data for these were most frequently reported within the reported studies, thus we were not able to examine the relative risk of mortality of other cancer types. Secondly, it was not possible to compare solid cancers to a control non-cancer cohort as there were no suitable studies identified. Thirdly, we are unable to explore the potential effects of different SARS-CoV-2 variants given this information was not available. Finally, the data included in this meta-analysis is in the pre-vaccination and anti-viral medication part of the pandemic, and therefore vaccinations and active treatments may impact on the observations made within this meta-analysis.

Conclusion

In this large and comprehensive analysis of the available data we demonstrate a higher risk of death from COVID-19 for cancer patients when compared to non-cancer patients, although the risk is lower than that reported by individual cohort studies. Younger patients are shown to be at particular increased risk of poor clinical outcomes when compared to age-matched controls. With lung cancer patients having the highest risk of mortality, along with patients with haematological malignancies. Given these data, younger patients must be classified as being a high-risk population. On-going studies such as CCP-Cancer-UK will enable a comparison of non-cancer versus cancer patients controlled for age, sex and other co-morbidities as well as dissecting the true risk different tumour types and treatment controlling for patient level factors. Studies are also needed to assess the impact of mitigation and treatment measures over the time course of the pandemic between cancer and non-cancer patients particularly given many of the treatment studies did not recruit cancer patients. The global effort to understand the effects of SARS-CoV-2 on cancer patients has resulted in a rich data resource which should be utilised for an individual patient level meta-analysis. Such data will be vital in ensuring we maximize our learning and knowledge and to prepare the cancer community for the subsequent pandemics which will inevitability occur.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Funding

EK: This work was supported by North West Cancer Research Fund to support an MRes (Award number CR1054).

LT is supported by a Wellcome Trust fellowship [205228/Z/16/Z]. This research was funded in whole, or in part, by the Wellcome Trust. For the purpose of Open Access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. LT is also supported by the U.S. Food and Drug Administration Medical Countermeasures Initiative contract 75F40120C00085 and by the National Institute for Health Research Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections (NIHR200907) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. LT is based at University of Liverpool. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England.

Competing Interests

LT has received speakers’ fees, paid to the University of Liverpool, from Eisai ltd for lecturing on cancer and COVID-19

CP Grant funding from Pfizer and Daiichi Sankyo and honoraria from Pfizer, Roche, Daiichi Sankyo, Novartis, Exact sciences, Gilead, SeaGen and Eli Lilly.

All remaining authors have declared no conflicts of interest.

Acknowledgments

The authors acknowledge support from UK Research Innovation (UKRI)-Department for Health and Social Care (DHSC) COVID-19 Rapid Response Rolling Call (Grant reference MR/V028979/1), The Liverpool Experimental Cancer Medicine Centre [Grant Reference: C18616/A25153], Cancer Research UK, The Clatterbridge Cancer Charity and North West Cancer.

Footnotes

  • Social media handles: E.K: @emmakhoury_

    S.N: @sjn_16

    L.T: @LanceTurtle

    C.P: @cancermedic

References

  1. 1.↵
    Chemaly RF, Vigil KJ, Saad M, et al. A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes. Cancer 2012; 118(18): 4627–33.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Dignani MC, Costantini P, Salgueira C, et al. Pandemic 2009 Influenza A (H1N1) virus infection in cancer and hematopoietic stem cell transplant recipients; a multicenter observational study. F1000Res 2014; 3: 221.
    OpenUrl
  3. 3.↵
    Campbell AP, Guthrie KA, Englund JA, et al. Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. Clin Infect Dis 2015; 61(2): 192–202.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Docherty AB, Harrison EM, Green CA, et al. Features of 201133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369: m1985.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Richards-Belle A, Orzechowska I, Gould DW, et al. COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland. Intensive Care Med 2020; 46(11): 2035–47.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Ferrando-Vivas P, Doidge J, Thomas K, et al. Prognostic Factors for 30-Day Mortality in Critically Ill Patients With Coronavirus Disease 2019: An Observational Cohort Study. Crit Care Med 2021; 49(1): 102–11.
    OpenUrlCrossRef
  7. 7.↵
    Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol 2021; 32(6): 787–800.
    OpenUrlCrossRef
  8. 8.↵
    Sharafeldin N, Bates B, Song Q, et al. Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C). Journal of Clinical Oncology; 0(0): JCO.21.01074.
  9. 9.↵
    Lièvre A, Turpin A, Ray-Coquard I, et al. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19). European Journal of Cancer 2020; 141: 62–81.
    OpenUrl
  10. 10.↵
    Pinato DJ, Zambelli A, Aguilar-Company J, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov 2020; 10(10): 1465–74.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. The Lancet Haematology 2020; 7(10): e737–e45.
    OpenUrl
  12. 12.↵
    Miyashita H, Mikami T, Chopra N, et al. Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol 2020; 31(8): 1088–9.
    OpenUrlPubMed
  13. 13.↵
    Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nature Medicine 2020; 26(8): 1218–23.
    OpenUrlPubMed
  14. 14.↵
    Tian JB, Yuan XL, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncology 2020; 21(7): 893–903.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Di Cosimo S, Tagliaferri B, Generali D, et al. Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study. Cancers (Basel) 2021; 13(6).
  16. 16.↵
    Mehta V, Goel S, Kabarriti R, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer discovery 2020; 10(7): 935–41.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 2020; 136(10): 1134–43.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Martínez-López J, Mateos MV, Encinas C, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer Journal 2020; 10(10).
  19. 19.↵
    Brar G, Pinheiro LC, Shusterman M, et al. COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. Journal of Clinical Oncology 2020; 38(33): 3914–24.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Zhang H, Wang L, Chen Y, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer 2020; 126(17): 4023–31.
    OpenUrl
  21. 21.↵
    Dai M, Liu D, Liu M, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer discovery 2020; 10(6): 783–91.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    Singh SRK, Thanikachalam K, Jabbour-Aida H, Poisson LM, Khan G. Covid-19 and cancer: Lessons learnt from a michigan hotspot. Cancers 2020; 12(9): 1–13.
    OpenUrlCrossRef
  23. 23.↵
    Shah V, Ko TK, Zuckerman M, et al. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital experience. British Journal of Haematology 2020; 190(5): E279–E82.
    OpenUrl
  24. 24.↵
    Rogado J, Obispo B, Pangua C, et al. Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. Clinical and Translational Oncology 2020; 22(12): 2364–8.
    OpenUrl
  25. 25.↵
    Sanchez-Pina JM, Rodríguez Rodriguez M, Castro Quismondo N, et al. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. European Journal of Haematology 2020; 105(5): 597–607.
    OpenUrlCrossRefPubMed
  26. 26.↵
    Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology 2020; 21(3): 335–7.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Ferrari BL, Ferreira CG, Menezes M, et al. Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil. JCO Global Oncology 2021; (7): 46–55.
  28. 28.↵
    Lee LYW, Cozier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncology 2020; 21(10): 1309–16.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Yigenoglu TN, Ata N, Altuntas F, et al. The outcome of COVID-19 in patients with hematological malignancy. Journal of Medical Virology 2020.
  30. 30.↵
    de Joode K, Dumoulin DW, Tol J, et al. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. European Journal of Cancer 2020; 141: 171–84.
    OpenUrl
  31. 31.↵
    Jee J, Foote MB, Lumish M, et al. Chemotherapy and COVID-19 Outcomes in Patients With Cancer. Journal of Clinical Oncology 2020; 38(30): 3538–46.
    OpenUrlPubMed
  32. 32.↵
    Martín-Moro F, Marquet J, Piris M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. British Journal of Haematology 2020; 190(1): e16–e20.
    OpenUrl
  33. 33.↵
    Basse C, Diakite S, Servois V, et al. Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients. JNCI Cancer Spectrum 2021; 5(1).
  34. 34.↵
    Mehta A, Vasudevan S, Parkash A, Sharma A, Vashist T, Krishna V. COVID-19 mortality in cancer patients: a report from a tertiary cancer centre in India. PeerJ 2021; 9: e10599.
    OpenUrlCrossRef
  35. 35.↵
    Yarza R, Bover M, Paredes D, et al. SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. European journal of cancer (Oxford, England : 1990) 2020; 135: 242–50.
    OpenUrlPubMed
  36. 36.↵
    Johannesen TB, Smeland S, Aaserud S, et al. COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway. Frontiers in Oncology 2021; 11(1010).
  37. 37.↵
    Rüthrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol 2020: 1–11.
  38. 38.↵
    Montopoli M, Zumerle S, Vettor R, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Annals of oncology : official journal of the European Society for Medical Oncology 2020; 31(8): 1040–5.
    OpenUrl
  39. 39.↵
    Meng Y, Lu W, Guo E, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol 2020; 13(1): 75.
    OpenUrlCrossRefPubMed
  40. 40.↵
    Cattaneo C, Daffini R, Pagani C, et al. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. Cancer 2020; 126(23): 5069–76.
    OpenUrlCrossRefPubMed
  41. 41.↵
    Sun L, Surya S, Le AN, et al. Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients. JNCI Cancer Spectr 2021; 5(1): pkaa120.
    OpenUrl
  42. 42.↵
    Stroppa EM, Toscani I, Citterio C, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future oncology (London, England) 2020; 16(20): 1425–32.
    OpenUrl
  43. 43.↵
    He WJ, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia 2020; 34(6): 1637–45.
    OpenUrlPubMed
  44. 44.↵
    Lunski MJ, Burton J, Tawagi K, et al. Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana. Cancer 2021; 127(2): 266–74.
    OpenUrlCrossRefPubMed
  45. 45.↵
    Joharatnam-Hogan N, Hochhauser D, Shiu K-K, et al. Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience. Therapeutic Advances in Medical Oncology 2020; 12: 1758835920956803.
    OpenUrl
  46. 46.↵
    Garassino MC, Whisenant JG, Huang L-C, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. The Lancet Oncology 2020; 21(7): 914–22.
    OpenUrlCrossRefPubMed
  47. 47.↵
    Özdemir N, Dizdar Ö, Yazici O, et al. Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data. Int J Cancer 2020.
  48. 48.↵
    Lara OD, O’Cearbhaill RE, Smith MJ, et al. COVID-19 outcomes of patients with gynecologic cancer in New York City. Cancer 2020; 126(19): 4294–303.
    OpenUrlPubMed
  49. 49.↵
    Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2020; 31(10): 1386–96.
    OpenUrl
  50. 50.↵
    Cook G, John Ashcroft A, Pratt G, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. British Journal of Haematology 2020; 190(2): e83–e6.
    OpenUrlPubMed
  51. 51.↵
    Booth S, Willan J, Wong H, et al. Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy. European Journal of Haematology 2020; 105(4): 476–83.
    OpenUrl
  52. 52.↵
    Vuagnat P, Frelaut M, Ramtohul T, et al. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. Breast Cancer Research 2020; 22(1): 55.
    OpenUrlPubMed
  53. 53.↵
    Wang B, Van Oekelen O, Mouhieddine TH, et al. A tertiary center experience of multiple myeloma patients with COVID-19: Lessons learned and the path forward. Journal of Hematology and Oncology 2020; 13(1).
  54. 54.↵
    Fox TA, Troy-Barnes E, Kirkwood AA, et al. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo-or immunotherapy. British Journal of Haematology 2020; 191(2): 194–206.
    OpenUrl
  55. 55.↵
    Kalinsky K, Accordino MK, Hosi K, et al. Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City. Breast Cancer Res Treat 2020; 182(1): 239–42.
    OpenUrl
  56. 56.↵
    Malard F, Genthon A, Brissot E, et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant 2020; 55(11): 2180–4.
    OpenUrlPubMed
  57. 57.↵
    Bogani G, Ditto A, Bosio S, Brusadelli C, Raspagliesi F. Cancer patients affected by COVID-19: Experience from Milan, Lombardy. Gynecologic Oncology 2020; 158(2): 262–5.
    OpenUrlPubMed
  58. 58.↵
    Lattenist R, Yildiz H, De Greef J, Bailly S, Yombi JC. COVID-19 in Adult Patients with Hematological Disease: Analysis of Clinical Characteristics and Outcomes. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2020: 1–5.
  59. 59.↵
    Hultcrantz M, Richter J, Rosenbaum CA, et al. COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discovery 2020; 1(3): 234–43.
    OpenUrlAbstract/FREE Full Text
  60. 60.↵
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
    OpenUrlFREE Full Text
  61. 61.↵
    Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014; 2014.
  62. 62.↵
    Fisher DJ. Two-stage Individual Participant Data Meta-analysis and Generalized Forest Plots. The Stata Journal 2015; 15(2): 369–96.
    OpenUrl
  63. 63.↵
    Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Archives of Public Health 2014; 72(1): 39.
    OpenUrl
  64. 64.↵
    Harbord RM, Higgins JPT. Meta-Regression in Stata. The Stata Journal 2008; 8(4): 493–519.
    OpenUrl
  65. 65.↵
    Grasselli G, Greco M, Zanella A, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Internal Medicine 2020; 180(10): 1345–55.
    OpenUrl
  66. 66.↵
    Yang KY, Sheng YH, Huang CL, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncology 2020; 21(7): 904–13.
    OpenUrlCrossRefPubMed
  67. 67.↵
    Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 2020; 34(9): 2354–63.
    OpenUrlCrossRef
  68. 68.↵
    de Melo AC, Thuler LCS, da Silva JL, et al. Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute. PLoS One 2020; 15(10): e0241261.
    OpenUrl
  69. 69.↵
    Albiges L, Foulon S, Bayle A, et al. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nature Cancer 2020; 1(10): 965–75.
    OpenUrl
  70. 70.↵
    Russell B, Moss C, Papa S, et al. Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy’s Cancer Center in London. Frontiers in Oncology 2020; 10.
  71. 71.
    Fratino L, Procopio G, Di Maio M, Cinieri S, Leo S, Beretta G. Coronavirus: Older Persons With Cancer in Italy in the COVID-19 Pandemic. Frontiers in oncology 2020; 10: 648-.
    OpenUrl
  72. 72.↵
    Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Critical Care 2020; 24(1): 179.
    OpenUrlCrossRefPubMed
  73. 73.
    Kabarriti R, Brodin NP, Maron MI, et al. Extent of Prior Lung Irradiation and Mortality in COVID-19 Patients With a Cancer History. Advances in Radiation Oncology 2020; 5(4): 707–10.
    OpenUrl
  74. 74.↵
    Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol 2020; 92(10): 2067–73.
    OpenUrlPubMed
  75. 75.↵
    Suleyman G, Fadel RA, Malette KM, et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Network Open 2020; 3(6): e2012270–e.
    OpenUrl
  76. 76.↵
    Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: A single center’s retrospective study. Journal of Infection 2020; 81(2): 318–56.
    OpenUrlCrossRefPubMed
  77. 77.↵
    Aries JA, Davies JK, Auer RL, et al. Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. British Journal of Haematology 2020; 190(2): e64–e7.
    OpenUrl
  78. 78.↵
    Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020; 31(7): 894–901.
    OpenUrlPubMed
  79. 79.↵
    Tomlins J, Hamilton F, Gunning S, Sheehy C, Moran E, MacGowan A. Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort. J Infect 2020; 81(2): e59–e61.
    OpenUrlPubMed
  80. 80.↵
    Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect 2020; 80(6): 639–45.
    OpenUrlCrossRefPubMed
  81. 81.↵
    Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncology 2020; 6(7): 1108–10.
    OpenUrl
  82. 82.↵
    Wu Q, Chu Q, Zhang H, et al. Clinical outcomes of coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to immune checkpoint inhibitors. Cancer Communications 2020; 40(8): 374–9.
    OpenUrlPubMed
  83. 83.↵
    Erdal GS, Polat O, Erdem GU, et al. The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study. Int J Clin Oncol 2021; 26(5): 826–34.
    OpenUrl
  84. 84.↵
    Guan W-j, Liang W-h, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. European Respiratory Journal 2020; 55(5): 2000547.
    OpenUrlAbstract/FREE Full Text
  85. 85.↵
    Song K, Gong H, Xu B, et al. Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID-19: A multicenter study. Cancer 2021; 127(3): 437–48.
    OpenUrl
  86. 86.↵
    Nepogodiev D, Bhangu A, Glasbey JC, et al. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. The Lancet 2020; 396(10243): 27–38.
    OpenUrlPubMed
  87. 87.↵
    Angelis V, Tippu Z, Joshi K, et al. Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. Eur J Cancer 2020; 136: 99–106.
    OpenUrlCrossRef
  88. 88.
    Assaad S, Avrillon V, Fournier ML, et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. European Journal of Cancer 2020; 135: 251–9.
    OpenUrl
  89. 89.↵
    Ciceri F, Castagna A, Rovere-Querini P, et al. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol 2020; 217: 108509.
    OpenUrlCrossRefPubMed
  90. 90.↵
    Tagliamento M, Lambertini M, Genova C, et al. Call for ensuring cancer care continuity during COVID-19 pandemic. ESMO Open 2020; 5(3): e000783.
    OpenUrlFREE Full Text
  91. 91.↵
    Gupta S, Hayek SS, Wang W, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Internal Medicine 2020; 180(11): 1436–47.
    OpenUrl
  92. 92.↵
    Desai A, Gupta R, Advani S, et al. Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. Cancer 2021; 127(9): 1459–68.
    OpenUrlCrossRefPubMed
  93. 93.↵
    Palmieri C, Palmer D, Openshaw PJM, Baille JK, Semple MG, Turtle L. Cancer datasets and the SARS-CoV-2 pandemic: Establishing principles for collaboration. ESMO Open 2020; 5(3).
  94. 94.↵
    Palmieri C, Turtle L, Drake T, et al. LBA60 Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK. Annals of Oncology 2021; 32: S1337–S.
    OpenUrl
Back to top
Posted December 19, 2021.
Download PDF

Supplementary Material

Data/Code
Email
A comprehensive systematic review and meta-analysis of the global data involving 61,532 cancer patients with SARS-CoV-2 infection
Emma Khoury, Sarah Nevitt, William Rohde Madsen, Lance Turtle, Gerry Davies, Carlo Palmieri
medRxiv 2021.12.18.21267261; doi: https://doi.org/10.1101/2021.12.18.21267261
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area